• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LAMOTRIGINE Drug Record

  • Summary
  • Interactions
  • Claims
  • LAMOTRIGINE chembl:CHEMBL741 Approved

    Alternate Names:

    LAMICTAL CD
    LAMOTRIGINE
    BW-430C
    LAMICTAL ODT
    LAMICTAL
    LAMICTAL XR
    LAMOTRIGINUM
    QÍN
    LAMICTAL®
    LAMOTRIGINA
    3,5-DIAMINO-6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE
    GIZORD
    QIN
    drugbank:00555
    pubchem.compound:3878
    chembl:CHEMBL741
    rxcui:28439
    chemidplus:84057-84-1

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications anticonvulsant
    (3 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Milosheska D et al., 2016, Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters., Br J Clin Pharmacol
    Inoue K et al., 2016, Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy., Eur J Clin Pharmacol
    Zhou Y et al., 2015, Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients., Drug Metab Pharmacokinet
    Singkham N et al., 2013, Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients., Eur J Clin Pharmacol
    Lipkind et al., 2005, Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels., Mol. Pharmacol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
    Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics
    Shen CH et al., 2016, Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy., Epilepsy Res
    Aberg et al., 1997, Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL)., Neuropediatrics
    Kazeem GR et al., 2009, High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients., Pharmacogenet Genomics
    Klarica Domjanović I et al., 2018, Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy., Br J Clin Pharmacol
    Chang Y et al., 2014, Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China., Eur J Clin Pharmacol
    Zhou J et al., 2011, Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes., Pharmacogenomics
    Bertok S et al., 2017, The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy., Seizure
    Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
    Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet
    Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem
  • LAMOTRIGINE   PPT1

    Interaction Score: 2.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9151331


    Sources:
    NCI

  • LAMOTRIGINE   UGT1A4

    Interaction Score: 1.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791014 26790665 24820767 23263737 22047493


    Sources:
    PharmGKB

  • LAMOTRIGINE   AQP4

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18572411


    Sources:
    DTC

  • LAMOTRIGINE   UGT2B7

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27096250 26790665 26213157 23263737


    Sources:
    PharmGKB

  • LAMOTRIGINE   HNF4A

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27610747 26213157


    Sources:
    PharmGKB

  • LAMOTRIGINE   HLA-C

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19668019


    Sources:
    PharmGKB

  • LAMOTRIGINE   HLA-DQB1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19668019


    Sources:
    PharmGKB

  • LAMOTRIGINE   SLC22A1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27610747


    Sources:
    PharmGKB

  • LAMOTRIGINE   SCN2A

    Interaction Score: 0.32

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Lamictal
    Novel drug target Established target
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    16174788 17016423 17139284 25155934 18784617


    Sources:
    TdgClinicalTrial ChemblInteractions PharmGKB

  • LAMOTRIGINE   SCN1A

    Interaction Score: 0.28

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    28753467 25155934 23859570 21747585 16174788


    Sources:
    ChemblInteractions PharmGKB

  • LAMOTRIGINE   ABCG2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791014 27610747 26213157


    Sources:
    PharmGKB

  • LAMOTRIGINE   HLA-DRB1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19668019


    Sources:
    PharmGKB

  • LAMOTRIGINE   SCN11A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • LAMOTRIGINE   SCN7A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LAMOTRIGINE   SCN8A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LAMOTRIGINE   SCN3A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LAMOTRIGINE   SCN4A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LAMOTRIGINE   SCN9A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LAMOTRIGINE   SCN10A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LAMOTRIGINE   SCN5A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LAMOTRIGINE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • LAMOTRIGINE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • LAMOTRIGINE   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMOTRIGINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • LAMOTRIGINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • LAMOTRIGINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TdgClinicalTrial: LAMOTRIGINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications anticonvulsant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: LAMOTRIGINE

    • Version: 14-September-2017

    Alternate Names:
    C38703 NCI drug code

    Drug Info:

    Publications:
    Aberg et al., 1997, Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL)., Neuropediatrics

  • DTC: LAMOTRIGINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL741 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem

  • PharmGKB: lamotrigine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Shen CH et al., 2016, Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy., Epilepsy Res
    Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
    Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet

  • TTD: Lamotrigine

    • Version: 2020.06.01

    Alternate Names:
    D03FLC TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL741

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL741

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21